HK1249913A1 - 治疗支气管肺发育不良的抗flt-1抗体 - Google Patents

治疗支气管肺发育不良的抗flt-1抗体 Download PDF

Info

Publication number
HK1249913A1
HK1249913A1 HK18109380.9A HK18109380A HK1249913A1 HK 1249913 A1 HK1249913 A1 HK 1249913A1 HK 18109380 A HK18109380 A HK 18109380A HK 1249913 A1 HK1249913 A1 HK 1249913A1
Authority
HK
Hong Kong
Prior art keywords
flt
bpd
bronchopulmonary dysplasia
antibodies
present
Prior art date
Application number
HK18109380.9A
Other languages
English (en)
Chinese (zh)
Inventor
Dennis KEEFE
Hans De Haard
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of HK1249913A1 publication Critical patent/HK1249913A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18109380.9A 2015-04-07 2016-04-07 治疗支气管肺发育不良的抗flt-1抗体 HK1249913A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144247P 2015-04-07 2015-04-07
US62/144,247 2015-04-07
PCT/US2016/026436 WO2016164579A1 (en) 2015-04-07 2016-04-07 Anti-flt-1 antibodies in treating bronchopulmonary dysplasia

Publications (1)

Publication Number Publication Date
HK1249913A1 true HK1249913A1 (zh) 2018-11-16

Family

ID=55795198

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18109380.9A HK1249913A1 (zh) 2015-04-07 2016-04-07 治疗支气管肺发育不良的抗flt-1抗体

Country Status (10)

Country Link
US (2) US10711065B2 (cg-RX-API-DMAC7.html)
EP (2) EP3280735B1 (cg-RX-API-DMAC7.html)
JP (2) JP6797825B2 (cg-RX-API-DMAC7.html)
CN (1) CN107683143A (cg-RX-API-DMAC7.html)
AU (3) AU2016246738B2 (cg-RX-API-DMAC7.html)
CA (1) CA2981961A1 (cg-RX-API-DMAC7.html)
HK (1) HK1249913A1 (cg-RX-API-DMAC7.html)
MA (1) MA41900A (cg-RX-API-DMAC7.html)
MX (1) MX2017012831A (cg-RX-API-DMAC7.html)
WO (1) WO2016164579A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3768299A1 (en) * 2018-03-22 2021-01-27 The Children's Medical Center Corporation Methods and compositions relating to lung repair
JP2021535896A (ja) * 2018-06-22 2021-12-23 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 気管支肺異形成症の治療における抗Ｆｌｔ−１抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308507B1 (en) * 2002-07-19 2015-01-14 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
US7972596B2 (en) 2004-11-18 2011-07-05 Imclone Llc Antibodies against vascular endothelial growth factor receptor-1
US20060153835A1 (en) * 2005-01-12 2006-07-13 Smith Henry J Treatment of pre-eclampsia in pregnant women using targeted apheresis
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
CA2826563C (en) * 2011-02-07 2020-10-20 Paul Kussie Methods and systems for treating eclampsia and pre-eclampsia
EA037501B1 (ru) * 2013-01-28 2021-04-05 Шир Хьюман Дженетик Терапис, Инк. Способ лечения мышечной дистрофии дюшенна путем введения анти-flt-1-антитела
TW201517916A (zh) 2013-03-15 2015-05-16 Lilly Co Eli Ｖｅｇｆｒ１抗體之治療用途

Also Published As

Publication number Publication date
AU2016246738B2 (en) 2021-12-16
JP2021014473A (ja) 2021-02-12
AU2022201781A1 (en) 2022-04-07
AU2022201781B2 (en) 2024-07-18
EP4063390A1 (en) 2022-09-28
EP3280735B1 (en) 2022-02-16
BR112017021416A2 (pt) 2018-07-03
EP3280735A1 (en) 2018-02-14
AU2016246738A1 (en) 2017-10-26
MA41900A (fr) 2021-06-02
US10711065B2 (en) 2020-07-14
US20210130475A1 (en) 2021-05-06
CA2981961A1 (en) 2016-10-13
US20180100017A1 (en) 2018-04-12
AU2024227035A1 (en) 2024-10-24
MX2017012831A (es) 2018-05-04
JP2018517667A (ja) 2018-07-05
CN107683143A (zh) 2018-02-09
JP6797825B2 (ja) 2020-12-09
WO2016164579A1 (en) 2016-10-13
AU2016246738A8 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
MX362105B (es) Folistatina en el tratamiento de distrofia muscular de duchenne.
MX2015008623A (es) Anticuerpos que se unen al ligando 1a tipo tnf y sus usos.
EP3552665A3 (en) Antibodies
MX2015009690A (es) Anticuerpos anti-flt-1 para tratar la distrofia muscular de duchenne.
UA94576C2 (ru) Выделенное антитело, которое связывается с igf-1r, композиция, которая его содержит, и способы, которые касаются антител
SA518390944B1 (ar) أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها
ZA201807920B (en) Anti¿gitr antibodies and uses thereof
MX2021015309A (es) Composiciones para el tratamiento de la artritis reumatoide y metodos para su uso.
AR105267A1 (es) Anticuerpos de unión a tau
MX2018003713A (es) Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente).
HK1249908A1 (zh) 治疗支气管肺发育不良的抗flt-1抗体
WO2017152090A3 (en) Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy
MY210018A (en) Monoclonal antibody that binds specifically to gitr
MX2025002470A (es) Combinaciones de anticuerpos anti-c5 y usos de las mismas
MX2019013523A (es) Proteínas de fusión de folistatina-fc recombinante y uso en el tratamiento de la distrofia muscular de duchenne.
BR112018009882A2 (pt) gradientes de ph-sal opostos para separações melhoradas de proteína
MX2017012828A (es) Anticuerpos anti-flt-1 para el tratamiento de distrofia muscular de duchenne.
HK1249913A1 (zh) 治疗支气管肺发育不良的抗flt-1抗体
WO2015198146A3 (en) Anti-il4-il 13 bispecific antibodies
PH12022551401A1 (en) Antibodies for the treatment of chronic graft versus host disease
WO2020033926A3 (en) Antibodies that bind cd277 and uses thereof
WO2020252394A3 (en) Targets and methods of diagnosing, monitoring and treating frontotemporal dementia
WO2015105806A3 (en) Antibodies against glioma biomarkers
MX2018009696A (es) Anticuerpos contra polipeptidos del antigeno leucocitario mano (hla) citrulinados y usos de estos.